Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Jerrold Turner
Brigham and Women's Hospital, Department: Na
Should you be removed from our database? Contact us at [email protected]. Read more below.
Thelium Therapeutics
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
This competitive renewals seeks to identify the intracellular protein interactions modified by Divertin and define the molecular mechanisms of MLCK1 recruitment to further understand the mechanisms and impact of intestinal epithelial barrier dysfunction. Thelium Therapeutics is developing therapeutics to restore epithelial and endothelial tissue barriers that target the same pathway. Given the private equity interest, it was determined that it was related and a financial conflict of interest as defined by the PHS regulations.
Perijunctional myosin light chain kinase recruitment: A novel, non-enzymatic target for therapeutic intestinal barrier restoration
PROJECT NARRATIVE: The intestinal lining (epithelium) must maintain a barrier that keeps the intestinal contents separate from the remainder of the body. This function is frequently compromised in intestinal disease and has been implicated as an early step in disease development. The proposed studies will advance mechanistic understanding of barrier regulation and dysregulation and will lay a foundation for development of novel therapeutic approaches to improve human health.
Filed on July 29, 2019.
Tell us what you know about Jerrold Turner's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Jerrold Turner filed other conflict of interest disclosures with the NIH:
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Jerrold Turner | Brigham and Women's Hospital | Conflict of Interest | Thelium Therapeutics | Value cannot be readily determined |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.